# Maintenance Intermittent Therapy for Symptomatic GERD Patients

> **NCT00165841** · PHASE2 · COMPLETED · sponsor: **Eisai Inc.** · enrollment: 200 (actual)

## Conditions studied

- Gastroesophageal Reflux Disease

## Interventions

- **DRUG:** Rabeprazole 20 mg

## Key facts

- **NCT ID:** NCT00165841
- **Lead sponsor:** Eisai Inc.
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE2
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2004-10
- **Primary completion:** 2005-12
- **Final completion:** 2008-06
- **Target enrollment:** 200 (ACTUAL)
- **Last updated:** 2013-05-20


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT00165841

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT00165841, "Maintenance Intermittent Therapy for Symptomatic GERD Patients". Retrieved via AI Analytics 2026-07-29 from https://api.ai-analytics.org/clinical/NCT00165841. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*